Callyope
Callyope is a French clinical AI company that builds an audio-language foundation model for psychiatry, offering the Callyope Copilot platform and CallyoCare (CE-marked voice-based symptom assessment) to mental health clinicians, healthcare institutions, and research partners.
- Company typePrivate
- Founded2023
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Callyope does
Callyope is a French clinical AI company building a foundation model purpose-built for psychiatry. Its platform, branded as the Callyope Copilot, combines a proprietary audio-language foundation model trained on psychiatric voice, language, clinical context and behavioral signals with two commercial offerings: CallyoCare, a CE-marked Class I medical device for voice-based symptom assessment (over 90% accuracy on 10+ symptoms from 30 seconds of speech), and a set of clinical documentation tools (chart reviews, ambient scribe, document drafting) positioned as +50% more accurate than general-purpose LLMs for psychiatric workflows. The platform integrates with French EHR systems (Dossier Patient Informatisé) and is hosted on HDS-certified Google Cloud France infrastructure, supporting ISO 27001, HDS and GDPR compliance.
The company serves three primary customer segments: mental health clinicians and psychiatrists (documentation automation, symptom monitoring, EHR integration), patients under clinician supervision (voice journaling, validated questionnaires via iOS/Android app), and academic research institutions (clinical trials and foundation-model validation, with eight ongoing trials including Oxford, Harvard-affiliated centers and GHU Paris). Revenue is generated through B2B SaaS subscriptions licensed to healthcare institutions and care structures on annual, quote-based contracts; pricing is not publicly disclosed.
Callyope was founded in 2023 by Martin Denais (CEO) and Rachid Riad, is headquartered in Neuilly-sur-Seine, France, operates with 1-10 employees, and has raised €2.2 million in seed funding (November 2023) from 360 Capital and Bpifrance with EIC co-funding. Strategic partnerships include Google for Startups, AWS Pioneers Project 2026, the Digital Medicine Society (DiMe) DATAcc initiative, ADDF's Diagnostics Accelerator SpeechDx study, and deployments across French mental health institutions including INICEA, EPSM, CHU Brest, IMH and SOS Medecins.
Callyope firmographics
Firmographics- Name
- Callyope
- Legal name
- CALLYOPE
- Website
- https://callyope.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Callyope is a French clinical AI company that builds an audio-language foundation model for psychiatry, offering the Callyope Copilot platform and CallyoCare (CE-marked voice-based symptom assessment) to mental health clinicians, healthcare institutions, and research partners.
- Ownership category
- akta.pro rank
Callyope industry classification
Industry- Product category
- Mental Health Clinical AI Software
- NAICS
- Offices of Mental Health Practitioners (except Physicians) (621330), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Psychiatry & Medication Management Platforms (HLALAEAB)
- akta.pro secondary industry
- Conversational AI Platforms (chat/voice bots, orchestration) (HDAAAFAC)
Keywords
Where Callyope is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Callyope business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- B2B SaaS Platform Subscription: Callyope offers its clinical AI platform to healthcare institutions and mental health clinicians through subscription-based licensing. The platform includes clinical documentation tools, symptom monitoring, and voice analysis capabilities. Access is provided via web interface for clinicians and mobile app for patients, with healthcare institutions partnering through formal care structure agreements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise healthcare institution licensing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Callyope product offering
Product offeringCore offering
Callyope sells a B2B clinical AI platform (Callyope Copilot) for mental health clinicians that combines AI-powered clinical documentation (chart reviews, ambient scribe, document drafting) with continuous patient symptom monitoring through voice analysis and validated questionnaires. The platform is powered by a proprietary audio-language foundation model trained specifically on psychiatric data, with CallyoCare — a CE-marked Class I medical device — providing voice-based symptom assessment that evaluates 10+ symptoms with over 90% accuracy from 30 seconds of speech.
Product overview
Callyope offers a unified clinical AI platform for mental health care centered on Callyope Copilot, the first AI copilot for mental health practitioners. The platform comprises two main components: the Callyope Copilot (web interface and mobile app) providing clinical documentation and patient monitoring capabilities, and CallyoCare, a Class I medical device (CE marked) enabling voice-based symptom assessment. Documentation features include Chart Reviews, Ambient Scribe, and Document Drafting. Patient monitoring includes Voice Journal and Validated Questionnaires. A proprietary audio-language foundation model trained on psychiatric data powers all capabilities, enabling transdiagnostic assessment across depression, anxiety, bipolar disorder, schizophrenia, and other conditions. Eight clinical trials are ongoing with leading institutions.
Differentiator
Problem solved
Functional benefit
Brands
- CallyoCare: A Class I medical device that assesses mental health symptoms through voice analysis, marked with CE certification. Part of the Callyope Copilot solution.
- Callyope Copilot
Products and services
- Callyope Copilot The first AI copilot for mental health clinicians, augmenting clinicians with medical data access through natural open-ended queries and delivering actionable insights via foundation-model-powered Software-as-a-Medical-Device capabilities. Combines clinical documentation automation with continuous patient symptom monitoring, accessible via web interface and mobile app.
- CallyoCare CE-marked Class I medical device that performs voice-based mental health symptom assessment, evaluating 10+ symptoms with over 90% accuracy from 30 seconds of speech. Used by clinicians for symptom tracking, continuous monitoring, and objective measurement of mental health conditions in clinical settings.
Quantifiable outcome
- Voice-based symptom assessment evaluates 10+ symptoms with over 90% accuracy from 30 seconds of speech
- +3 more outcomes
Companies that use Callyope
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Callyope technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature7 records
Callyope partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- SpeechDx / ADDF Diagnostics AcceleratorcoreCallyope licensed the SpeechDx longitudinal dataset generated by the ADDF's Diagnostics Accelerator initiative. SpeechDx is a three-year multinational observational study generating gold-standard data to train and validate AI-driven speech analysis tools for Alzheimer's detection. The dataset is also licensed by Siemens Healthineers. Gates Ventures and the $150M Diagnostics Accelerator back this initiative founded by Leonard A. Lauder and Bill Gates.
- Digital Medicine Society (DiMe)majorCallyope joined DiMe's DATAcc initiative to develop the first set of digital measures specifically designed for common mental health disorders. The initiative involves over 20 industry, advocacy, and research partners including Wellcome-commissioned work. Callyope contributes expertise in speech/language digital measures.
- StanecoreClinical trial partnership for major depression assessment. Callyope started a clinical trial with Stane to evaluate voice-based AI detection capabilities for major depressive disorder. This represents Callyope's expansion beyond schizophrenia, bipolar disorder, and severe depression monitoring.
- GHU PariscoreStrategic R&D partnership announced for collaborative research on AI-powered mental health monitoring. GHU Paris is a major psychiatric hospital group in Paris. Callyope and GHU Paris are working together on research initiatives for the Callyope Copilot platform.
- Oxford UniversitycoreLeading research partner in ongoing clinical trials. Oxford is one of the eight clinical trials currently validating Callyope's foundation model capabilities across depression, anxiety, insomnia, fatigue, and cognitive decline assessment.
- Google Cloud France SARLcoreDesignated health data hosting provider per Callyope's terms and conditions. Google Cloud France SARL, headquartered at 8 rue de Londres, Paris, provides HDS-certified infrastructure for storing and managing sensitive health data in compliance with French regulations.
- Google for StartupsmajorPartner through Google for Startups program supporting healthcare AI startups. Featured in Google's healthcare AI startup ecosystem. Provides credibility and access to Google Cloud resources and mentorship.
- Leading European Hospitals (CHU Brest, EPSM, IMH, SOS Medecins)coreMultiple leading French mental health institutions partner with Callyope for clinical trials, validation studies, and platform deployment. These include CHU Brest (university hospital), EPSM (public mental health institution), IMH (mental health institute), and SOS Medecins (emergency care provider).
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Callyope competitors and assessment
Company assessmentDirect peers
- Eleos Health: Eleos Health builds an AI-powered clinical documentation and analytics platform specifically for behavioral health clinicians, including ambient scribing for therapy sessions. It is the most direct US-based competitor to Callyope Copilot's clinical-documentation features for mental health practitioners.
- Kintsugi: Kintsugi uses voice biomarkers and machine learning to detect signs of depression and anxiety from short voice samples. It is a direct competitor to CallyoCare's voice-based symptom assessment offering in the digital mental health space.
- Ellipsis Health: Ellipsis Health applies AI to voice and text to measure and monitor mental health symptoms, including depression and anxiety severity. Comparable to Callyope's voice analysis and clinical-documentation workflows targeting payors, providers, and pharma.
- Suki AI: Suki AI offers an ambient AI assistant that generates clinical notes and documentation for physicians. While broader than psychiatry, it competes directly with Callyope's Ambient Scribe and Document Drafting modules across clinical workflows.
- Abridge: Abridge provides an ambient AI platform that converts patient-clinician conversations into structured clinical notes and integrates with EHR systems. It is a leading competitor to Callyope's ambient scribing and chart-review capabilities, though focused more broadly across specialties.
Emerging players
- Woebot Health: Woebot Health builds AI-driven conversational mental health tools for symptom monitoring and CBT-style support. Overlaps with Callyope's patient-facing Voice Journal and symptom-monitoring modules, though focused on automated therapy rather than clinician augmentation.
- Lyssn: Lyssn provides an AI platform for psychotherapy session analysis, including transcription and quality measurement. Compares to Callyope's psychiatric-focused documentation and chart review capabilities for mental health clinicians.
- Akili Interactive: Akili Interactive develops FDA-cleared digital therapeutics for mental health conditions such as ADHD and depression. Adjacent to Callyope's symptom-monitoring ambition, though focused on prescribed software rather than clinician AI augmentation.
- Sonde Health: Sonde Health analyzes vocal biomarkers to detect and monitor mental and respiratory health conditions. Direct overlap with CallyoCare's voice-based symptom assessment, although Sonde has broader ambitions across multiple therapeutic areas.
Broad incumbents
- Microsoft (Nuance DAX): Nuance DAX, now part of Microsoft, is a leading enterprise ambient clinical documentation solution for hospitals and health systems. Represents the broad-incumbent threat to Callyope's ambient scribe, with deep EHR integration and large enterprise sales reach.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Callyope social profiles
Digital presenceCallyope compliance and trust
Trust signalCompliance4 records
Callyope financial estimates
Financial estimateRevenue estimate
Valuation estimate
Callyope leadership team
Management profileNumber of profiles
Profiles2 records
Callyope funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Callyope M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Callyope
What does Callyope do?
Callyope sells a B2B clinical AI platform (Callyope Copilot) for mental health clinicians that combines AI-powered clinical documentation (chart reviews, ambient scribe, document drafting) with continuous patient symptom monitoring through voice analysis and validated questionnaires. The platform is powered by a proprietary audio-language foundation model trained specifically on psychiatric data, with CallyoCare — a CE-marked Class I medical device — providing voice-based symptom assessment that evaluates 10+ symptoms with over 90% accuracy from 30 seconds of speech.
Is Callyope a public or private company?
Callyope is a private company. It is classified as venture growth investor backed and is currently operating.
When was Callyope founded?
Callyope was founded in 2023. It employs 1 to 10 people.
Where is Callyope based?
Callyope is headquartered in Paris, France, in the Europe region.
How does Callyope make money?
One revenue line is on record: B2B SaaS Platform Subscription.
Who are Callyope's main competitors?
Direct peers on record are Eleos Health, Kintsugi, Ellipsis Health, Suki AI and Abridge. Emerging players are Woebot Health, Lyssn, Akili Interactive and Sonde Health. Microsoft (Nuance DAX) is listed as a broad incumbent.
Does Callyope have an API?
No public API is recorded for Callyope.
What industry is Callyope in?
Callyope's product category is Mental Health Clinical AI Software. Its primary akta.pro industry code is HLALAEAB, Psychiatry & Medication Management Platforms, with a secondary code of HDAAAFAC, Conversational AI Platforms (chat/voice bots, orchestration). Its NAICS code is 621330 and its SIC code is 7372.